Literature DB >> 18373953

Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity.

Chun Kwok Wong1, Lydia Choi Wan Lit, Lai Shan Tam, Edmund Kwok Ming Li, Purple Tsz Yan Wong, Christopher Wai Kei Lam.   

Abstract

IL-23-dependent IL-17-producing T helper (Th) lymphocytes are associated with autoimmunity. We investigated the immunopathological mechanisms for activation of Th17 cells of patients with systemic lupus erythematosus (SLE). Concentration of cytokines/chemokine in plasma and culture supernatant from SLE patients and healthy controls were measured by ELISA or flow cytometry. Plasma IL-12, IL-17, IL-23 and CXCL10 concentrations and the number of Th17 cells were significantly elevated in SLE patients than control subjects (both p<0.05). Elevated IL-12, IL-17 and CXCL10 concentrations correlated positively and significantly with SLEDAI (all p<0.05). Plasma IL-12 and IL-17 showed significant and positive correlation with plasma Th1 chemokine CXCL10 concentration in SLE patients (all p<0.05). Ex vivo inductions of IL-17 by IL-23 or IL-18 from co-stimulated lymphocytes were significantly higher in SLE patients than controls (all p<0.05). The activated IL-23/IL-17 axis is important for the inflammatory immunity in SLE.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18373953     DOI: 10.1016/j.clim.2008.01.019

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  194 in total

1.  Requirement of myeloid cell-specific Fas expression for prevention of systemic autoimmunity in mice.

Authors:  Carla M Cuda; Hemant Agrawal; Alexander V Misharin; G Kenneth Haines; Jack Hutcheson; Evan Weber; Joseph A Schoenfeldt; Chandra Mohan; Richard M Pope; Harris Perlman
Journal:  Arthritis Rheum       Date:  2012-03

2.  The role of interleukin-23/interleukin-17 axis in the development of systemic lupus erythematosus among patients with tuberculosis: comment on: Lin YC, Liang SJ, Liu YH et al.: tuberculosis as a risk factor for systemic lupus erythematosus: results of a nationwide study in Taiwan. (Rheumatol Int. 2011 Mar 18. [Epub ahead of print]).

Authors:  Se Jin Park; Ji Hong Kim; Tae Sun Ha; Jae Il Shin
Journal:  Rheumatol Int       Date:  2011-11-17       Impact factor: 2.631

Review 3.  Th17 cell dynamics in HIV infection.

Authors:  Nichole R Klatt; Jason M Brenchley
Journal:  Curr Opin HIV AIDS       Date:  2010-03       Impact factor: 4.283

4.  Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4-CD8- double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus.

Authors:  Hiroshi Kato; Andras Perl
Journal:  J Immunol       Date:  2014-03-28       Impact factor: 5.422

Review 5.  [Th17 cells - a new proinflammatory T cell population and its role in rheumatologic autoimmune diseases].

Authors:  J Leipe; A Skapenko; H Schulze-Koops
Journal:  Z Rheumatol       Date:  2009-07       Impact factor: 1.372

6.  miR-210 expression in PBMCs from patients with systemic lupus erythematosus and rheumatoid arthritis.

Authors:  Q Huang; S-S Chen; J Li; S-S Tao; M Wang; R-X Leng; H-F Pan; D-Q Ye
Journal:  Ir J Med Sci       Date:  2017-05-30       Impact factor: 1.568

7.  Increased circulating Th17 cell populations and elevated CSF osteopontin and IL-17 concentrations in patients with Guillain-Barré syndrome.

Authors:  Rong Kun Han; Yue Feng Cheng; Shan Shan Zhou; Hong Guo; Rui Dong He; Li Jun Chi; Li Ming Zhang
Journal:  J Clin Immunol       Date:  2013-11-12       Impact factor: 8.317

8.  Interplay between effector Th17 and regulatory T cells.

Authors:  Amit Awasthi; Gopal Murugaiyan; Vijay K Kuchroo
Journal:  J Clin Immunol       Date:  2008-09-23       Impact factor: 8.317

Review 9.  IL-17 in Renal Immunity and Autoimmunity.

Authors:  Partha S Biswas
Journal:  J Immunol       Date:  2018-12-01       Impact factor: 5.422

Review 10.  Interleukin-17 and systemic lupus erythematosus: current concepts.

Authors:  A Nalbandian; J C Crispín; G C Tsokos
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.